USAMMDA commercial partner receives FDA emergency use authorization for plasma powder (IMAGE)
Caption
Soldiers with the U.S. Army 11th Airborne Division test a Freeze-Dried Plasma kit as part of combat casualty care training during Joint Pacific Multinational Readiness Center (JPMRC), Fort Wainwright, Alaska, April 2, 2023. FDP is one of several human and canine blood products currently under development by the U.S. Army Medical Materiel Development Activity at Fort Detrick, Maryland. USAMMDA’s Warfighter Protection and Acute Care Project Management team partners with both U.S. Department of Defense and non-DOD industry development partners to develop and deliver blood products for possible future use by the military Joint-Forces. In August 2024, WPAC’s commercial partner, Octopharma, received an Emergency Use Authorization from the U.S. Food and Drug Administration allowing the DOD to use the company’s product, octaplasLG Powder, in circumstances when traditional blood plasma may not be available.
Credit
(U.S. Army Courtesy Photo/Released)
Usage Restrictions
No restrictions.
License
Public Domain